- Home
- IVVD vs BRNS Comparison
IVVD vs BRNS Comparison
Compare IVVD & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- BRNS
- Stock Information
- Founded
- IVVD 2020
- BRNS 2016
- Country
- IVVD United States
- BRNS United Kingdom
- Employees
- IVVD N/A
- BRNS N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- IVVD Health Care
- BRNS Health Care
- Exchange
- IVVD Nasdaq
- BRNS Nasdaq
- Market Cap
- IVVD 63.4M
- BRNS 58.0M
- IPO Year
- IVVD 2021
- BRNS 2021
- Fundamental
- Price
- IVVD $1.60
- BRNS $1.61
- Analyst Decision
- IVVD Strong Buy
- BRNS Strong Buy
- Analyst Count
- IVVD 5
- BRNS 1
- Target Price
- IVVD $5.11
- BRNS $3.00
- AVG Volume (30 Days)
- IVVD 4.4M
- BRNS 248.2K
- Earning Date
- IVVD 11-13-2025
- BRNS 11-05-2025
- Dividend Yield
- IVVD N/A
- BRNS N/A
- EPS Growth
- IVVD N/A
- BRNS N/A
- EPS
- IVVD N/A
- BRNS N/A
- Revenue
- IVVD $46,210,000.00
- BRNS $14,969,000.00
- Revenue This Year
- IVVD $112.35
- BRNS N/A
- Revenue Next Year
- IVVD $272.14
- BRNS N/A
- P/E Ratio
- IVVD N/A
- BRNS N/A
- Revenue Growth
- IVVD 1941.08
- BRNS 1766.46
- 52 Week Low
- IVVD $0.35
- BRNS $0.64
- 52 Week High
- IVVD $2.74
- BRNS $2.92
- Technical
- Relative Strength Index (RSI)
- IVVD 71.86
- BRNS 65.26
- Support Level
- IVVD $1.15
- BRNS $1.36
- Resistance Level
- IVVD $1.15
- BRNS $1.67
- Average True Range (ATR)
- IVVD 0.12
- BRNS 0.17
- MACD
- IVVD 0.02
- BRNS 0.05
- Stochastic Oscillator
- IVVD 99.85
- BRNS 72.15
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.